Unknown

Dataset Information

0

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.


ABSTRACT: Ketamine, an N-methyl-D-aspartate receptor (NMDAR) channel blocker, has been found to induce rapid and robust antidepressant-like effects in rodent models and in treatment-refractory depressed patients. However, the marked acute psychological side effects of ketamine complicate the interpretation of both preclinical and clinical data. Moreover, the lack of controlled data demonstrating the ability of ketamine to sustain the antidepressant response with repeated administration leaves the potential clinical utility of this class of drugs in question. Using quantitative electroencephalography (qEEG) to objectively align doses of a low-trapping NMDA channel blocker, AZD6765 (lanicemine), to that of ketamine, we demonstrate the potential for NMDA channel blockers to produce antidepressant efficacy without psychotomimetic and dissociative side effects. Furthermore, using placebo-controlled data, we show that the antidepressant response to NMDA channel blockers can be maintained with repeated and intermittent drug administration. Together, these data provide a path for the development of novel glutamatergic-based therapeutics for treatment-refractory mood disorders.

SUBMITTER: Sanacora G 

PROVIDER: S-EPMC4195977 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.

Sanacora G G   Smith M A MA   Pathak S S   Su H-L HL   Boeijinga P H PH   McCarthy D J DJ   Quirk M C MC  

Molecular psychiatry 20131015 9


Ketamine, an N-methyl-D-aspartate receptor (NMDAR) channel blocker, has been found to induce rapid and robust antidepressant-like effects in rodent models and in treatment-refractory depressed patients. However, the marked acute psychological side effects of ketamine complicate the interpretation of both preclinical and clinical data. Moreover, the lack of controlled data demonstrating the ability of ketamine to sustain the antidepressant response with repeated administration leaves the potentia  ...[more]

Similar Datasets

| S-EPMC5068814 | biostudies-literature
| S-EPMC7729946 | biostudies-literature
| S-EPMC6299069 | biostudies-literature
| S-EPMC5794893 | biostudies-literature
| S-EPMC5794873 | biostudies-literature
| S-EPMC2809336 | biostudies-literature
| S-EPMC4425283 | biostudies-literature
| S-EPMC3278496 | biostudies-literature
| S-EPMC5552878 | biostudies-other
| S-EPMC3935199 | biostudies-other